Get the Daily Brief
Latest Biotech News
Tetraneuron pursues upstream gene‑therapy angle for Alzheimer’s: E2F4 AAV program advances
Tetraneuron presented its E2F4‑focused AAV gene‑therapy approach aimed at upstream drivers of Alzheimer’s disease, arguing that modulating a transcription factor could prevent neurons from...
Deep learning accelerates antibiotic discovery: models mine chemical space for new scaffolds
Researchers reported application of deep‑learning models to rapidly identify novel antibiotic scaffolds and prioritize leads against resistant pathogens. The approach integrates large chemical...
Biogen bets $70M on Vanqua’s C5aR1 antagonist
Biogen has licensed exclusive global rights to Vanqua Bio’s preclinical C5aR1 antagonist, paying $70 million up front and agreeing to as much as $990 million in future milestones. The deal hands...
Lilly buys Adverum — snaps up phase‑3 eye gene therapy
Eli Lilly agreed to acquire cash‑strapped Adverum in a deal that secures ixo‑vec, an AAV‑based gene therapy in phase 3 for wet age‑related macular degeneration. The transaction trades a modest...
Inhibrx posts phase II win — eyes BLA for rare chondrosarcoma
Inhibrx reported that its monoclonal antibody ozekibart met the primary endpoint in a registrational phase II study for advanced or metastatic unresectable chondrosarcoma, producing a...
Gepotidacin wins approval for UTIs; gonorrhea filing pending
Gepotidacin, an oral bacterial type II topoisomerase inhibitor, received regulatory approval in March 2025 for uncomplicated urinary tract infections under the name Blujepa and remains under FDA...
FDA finds unauthorized API warehouse — contamination and compliance flagged
The U.S. Food and Drug Administration disclosed an inspection that uncovered an unauthorized warehouse tied to Indian generic drugmaker Hetero Labs storing drugs and active pharmaceutical...
Deep learning accelerates antibiotic discovery: two Nature Biotech papers
Two independent studies published in Nature Biotechnology show deep‑learning models dramatically speed antibacterial discovery by linking high‑throughput phenotypic screening data to structurally...
LNP blueprints... and a bespoke CRISPR made in months
New biophysical analyses have mapped diverse lipid nanoparticle (LNP) architectures and linked particle shape to delivery performance, while a coordinated academic‑industry effort rapidly...
Tetraneuron targets E2F4 — upstream gene therapy strategy for Alzheimer’s
Tetraneuron presented an AAV‑based gene therapy approach, TET‑101, that targets the transcription factor E2F4 to prevent aberrant neuronal cell‑cycle reentry—an upstream mechanism the company...
Takeda pays $1.2bn for Innovent oncology duo — global rights outside China
Takeda struck a $1.2 billion licensing and collaboration agreement with Innovent Biologics to acquire global rights (outside Greater China) to two late‑stage oncology candidates: IBI363, a...
Tango’s PRMT5 data satisfy — pivotal pancreatic study planned
Tango Therapeutics reported positive phase I/II results with vopimetostat (TNG‑462), a next‑generation MTA‑cooperative PRMT5 inhibitor, showing clinical activity in MTAP‑deleted pancreatic ductal...
Biogen licenses Vanqua's C5aR1 antagonist: $70M now, $990M possible
Biogen agreed to an exclusive worldwide license for Vanqua Bio’s preclinical C5aR1 antagonist, paying $70 million upfront and up to $990 million in milestones. Under the deal Biogen will lead...
FDA returns GSK’s Blenrep to market – approval limited to specific combos
The FDA granted a restricted approval for GSK’s antibody‑drug conjugate Blenrep, clearing it for use in combination with Velcade for patients whose multiple myeloma returned or progressed after at...
Lilly buys Adverum for gene therapy bet – cash rescue with CVR upside
Eli Lilly agreed to acquire cash‑strapped Adverum in a deal centered on ixo‑vec, the company’s phase‑3 intravitreal AAV gene therapy for wet age‑related macular degeneration. The transaction...
Inhibrx’s rare cancer win prompts BLA talk – regulators in view
Inhibrx reported registrational‑stage phase II results showing its monoclonal antibody ozekibart produced statistically significant and clinically meaningful progression‑free survival benefits in...
Tango’s PRMT5 data…pivotal path opens in pancreatic cancer
Tango Therapeutics released positive phase I/II data for vopimetostat (TNG‑462), a next‑generation PRMT5 inhibitor that leverages MTAP deletion cooperativity, showing encouraging activity in...
Takeda inks $1.2B oncology pact with Innovent — global rights outside China
Takeda signed a $1.2 billion licensing and collaboration agreement with China’s Innovent Biologics to obtain rights outside Greater China to two late‑stage oncology assets: IBI363, a...
AI accelerates antibiotic discovery: deep‑learning screens reveal new scaffolds
Two Nature Biotechnology reports demonstrate deep‑learning and virtual screening approaches that accelerate antibacterial discovery by surfacing structurally novel compounds from high‑throughput...
LNP shapes mapped: study links particle architecture to delivery performance
Researchers at the University of Pennsylvania, Brookhaven and industry partners published a detailed biophysical analysis of lipid nanoparticle (LNP) architectures, showing that LNPs adopt diverse...